Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 11, 2013, Pages 589-595

  Krawczyk, Katarzyna ^a   Jurczak, Wojciech ^a   Długosz Danecka, Monika ^a   Zauska Giza, Agnieszka ^a   Dzietczenia, Justyna ^b   Wróbel, Tomasz ^b   Skotnicki, Aleksander B ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Central nervous system prophylaxis; Liposomal cytarabine; Non Hodgkin lymphoma

Indexed keywords

ADM DOXORUBICIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; PREDNISONE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DRUG CARRIER; LIPOSOME; MONOCLONAL ANTIBODY; R-CHOP PROTOCOL;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM METASTASIS; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HIGH RISK PATIENT; HUMAN; HUNGARY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; NEUROLOGIC DISEASE; OVERALL SURVIVAL; POLAND; PROPHYLAXIS; VOMITING; YOUNG ADULT; CENTRAL NERVOUS SYSTEM DISEASES; COMPLICATION; DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM DISEASES; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, SPINAL; LIPOSOMES; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; VINCRISTINE; YOUNG ADULT;

EID: 84891867748     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.1968     Document Type: Article

References (29)

1. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program. 2009: 523-531.
2. Martelli M, Ferreri AJ, Agostinelli C, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013; 87: 146-171.
3. van Besien K, Kelta M, Bahaguna P. Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol. 2001; 19: 1855-1864.
4. Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. Hematol Oncol. 2013; 31: 10-17.
5. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing ritux-imab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116: 2040-2045.
6. Xu LM, Fang H, Wang WH, et al. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy. Leuk Lymphoma. 2013; 54: 1684-1690.
7. Chamberlain MC, Nolan C, Abrey LE. Leukemic and lymphomatous meningitis: incidence, prognosis and treatment. J Neurooncol. 2005; 75: 71-83.
8. Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012; 23: 1267-1273.
9. Yamamoto W, Tomita N, Watanabe R, et al. Central nervous system in-volvement in diffuse large B-cell lymphoma. Eur J Haematol. 2010; 85: 6-10.
10. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to ret-rospective analysis from a single-center experience. Int J Hematol. 2009; 89: 577-583.
11. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab. Ann Hematol. 2011; 90: 809-818.
12. Zhang J, Chen B, Xu X. Impact of rituximab on the incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2013 Jul 29. [Epub ahead of print].
13. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol. 1999; 17: 3110-3116.
14. Cortelazzo S, Ponzoni M, Ferreri AJ, Hoelzer D. Lymphoblastic lymphoma. Crit Rev Oncol Hematol. 2011; 79: 330-343.
15. Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003; 97: 3053-3060.
16. Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother. 2008; 9: 301-309.
17. Garcia-Marco JA, Panizo C, Garcia ES, et al. Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma. Cancer. 2009; 115: 1892-1898.
18. Sobocinski M, Jurczak W, Dzietczenia J, et al. Prophylaxis of central nervous system (CNS) relapse in high-risk lymphoma patients with liposomal cytarabine. J Clin Oncol (ASCO Annual Meeting). 2011; Suppl: e18 520.
19. Giebel S, Walewski J, Krawczyk-Kulis M, et al. [Prophylaxis and treatment of the central nervous system involvement in lymphoid malignancies]. Hematologia. 2010; 4: 352-358. Polish.
20. Chowdhary S, Chamberlain M. Leptomeningeal metastases: current concepts and management guidelines. J Natl Compr Canc Netw. 2005; 3: 693-703.
21. Guirguis HR, Cheung, MC, Mahrous M, et al. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol. 2012; 159: 39-49.
22. Sancho JM, Morgades M, Alonso N, et al. Prospective study on the practice of central nervous system prophylaxis and treatment in non-Hodgkin's lymphoma in Spain. Med Clin (Barc). 2008; 131: 441-446.
23. Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003; 102: 4284-4289.
24. Howell SB. Liposomal cytarabine for the treatment of lymphomatous meningitis. Biol Ther Lymphoma. 2003; 6: 10-14.
25. Nagpal S, Recht L. Treatment and prophylaxis of hematologic malignancy in the central nervous system. Curr Treat Options Neurol. 2011; 13: 400-412.
26. Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, et al. Neuro-logic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol. 2011; 103: 603-609.
27. Avilés A, Jesús Nambo M, Neri N. Central nervous system prophylaxis in patients with aggressive diffuse large B cell lymphoma: an analysis of 3,258 patients in a single center. Med Oncol. 2013; 30: 520.
28. Björkholm M, Hagberg H, Holte H. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol. 2007; 18: 1085-1089.
29. Kim S, Chatelut E, Kim JC, et al. Extended CSF cytarabine exposure following intrathecal administration of DTC 101. J Clin Oncol. 1993; 11: 2186-2193.